This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
September 07, 2012, 09:00 pm ET
Amy Glynn - VP, IR Ruth Group
Albert Eilender - Chairman & CEO
Sal Guccione - President & COO
Ronald Gold President & COO, Rising Pharmaceuticals
Douglas Roth - CFO
Bill Jones - Singular Research
Tony Pollock - Maxim Group
William Schaff - Phocas Financial
Lenny Dunn - Freedom Investors
Welcome to the Aceto Corporation fiscal 2012 fourth quarter results conference call. My name is Sandra and I'll be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference is being recorded.
This conference call may contain forward-looking statements as that term is defined in the federal securities laws. All statements that address expectations or projections about the future are forward-looking statements. Although they reflect our current expectations, these statements are not guarantees of future performance, but involving a number of risks and assumptions.
We're due to review Aceto’s filings with the SEC, including but not limited to Aceto’s annual report on Form 10-K for the fiscal year ended June 30, 2011 for a discussion of some of the factors that could cause actual results to differ materially. Copies of these filings are also available at www.sec.gov. We do not undertake any duty to update any forward-looking statements.
I'll now turn the call over to Amy Glynn, Vice President of Investor Relations at the Ruth Group.
Thank you. Good morning and welcome to Aceto Corporation fiscal 2012 fourth quarter and year end conference call audio webcast. With me today are Albert Eilender, Chairman of the Board and CEO, Sal Guccione President and COO, Ronald Gold, President and COO of Rising Pharmaceuticals and Douglas Roth, CFO of Aceto.